Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 23;10(1):e0141121.
doi: 10.1128/spectrum.01411-21. Epub 2022 Feb 9.

TNF-α Levels in Respiratory Samples Are Associated with SARS-CoV-2 Infection

Matias J Pereson #  1   2 , Maria Noel Badano #  1 , Natalia Aloisi  1 , Roberto Chuit  3 , M M E de Bracco  1 , Patricia Bare  1
Affiliations

TNF-α Levels in Respiratory Samples Are Associated with SARS-CoV-2 Infection

Matias J Pereson et al. Microbiol Spectr. .
No abstract available

Keywords: IL-6; SARS-CoV-2; cytokines; tumor necrosis factor.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIG 1
FIG 1
Population characteristics and cytokine concentration in swabs. (A) Population characteristics. Values are expressed as median (range) unless otherwise noted. pts, patients; F, female; M, male; Ct, cycle threshold; na, not applicable. (B) Cytokine levels from SARS-CoV-2 (+) and (–) symptomatic individuals are shown. Mean ± SEM for TNF-α (i) and IL-6 (ii) concentrations are expressed in log (pg/mL). Cytokines were measured in asymptomatic individuals negative for SARS-CoV-2 genome to set up normal ranges. All values below the limit of detection were considered as 5 pg/mL for statistical analysis purposes.
See this image and copyright information in PMC

References

    1. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A, Marron TU, Xie H, Patel M, Tuballes K, Van Oekelen O, Rahman A, Kovatch P, Aberg JA, Schadt E, Jagannath S, Mazumdar M, Charney AW, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S. 2020. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 26:1636–1643. doi:10.1038/s41591-020-1051-9. - DOI - PMC - PubMed
    1. Chen LYC, Hoiland RL, Stukas S, Wellington CL, Sekhon MS. 2020. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. Eur Respir J 56:2003006. doi:10.1183/13993003.03006-2020. - DOI - PMC - PubMed
    1. Zhang Y, Zhong Y, Pan L, Dong J. 2020. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: are we already that far? Drug Discov Ther 14:100–102. doi:10.5582/ddt.2020.03006. - DOI - PubMed
    1. Robinson PC, Richards D, Tanner HL, Feldmann M. 2020. Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. Lancet Rheumatol 2:e653–e655. doi:10.1016/S2665-9913(20)30309-X. - DOI - PMC - PubMed
    1. Robinson PC, Liew DFL, Liew JW, Monaco C, Richards D, Shivakumar S, Tanner HL, Feldmann M. 2020. The potential for repurposing anti-TNF as a therapy for the treatment of COVID-19. Med (N Y) 1:90–102. doi:10.1016/j.medj.2020.11.005. - DOI - PMC - PubMed

Publication types